BofA moves to No Rating on Patterson Companies (PDCO) after the company announced that it has signed a definitive agreement to be acquired by Patient Square Capital for $31.35 per share in cash. Despite current weakness in dental and companion animal health trends, the firm views the takeout valuation as “reasonable,” the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDCO:
- Patterson Companies price target raised to $31 from $25 at Baird
- M&A News: Patterson Companies Stock (PDCO) Rallies on Patient Square Deal
- Albertsons terminates Kroger deal, Macy’s reports Q3 beat: Morning Buzz
- Patterson Companies downgraded to Market Perform from Outperform at Leerink
- Patterson Companies to be acquired by Patient Square for $31.35 per share